The Actinic Keratosis (AK) Treatment Market, valued at USD 6.58 billion in 2022, is projected to experience a revenue Compound Annual Growth Rate (CAGR) of 4.7% during the forecast period. AK treatment encompasses various therapies aimed at managing and addressing actinic keratosis, a pre-cancerous skin condition caused by prolonged exposure to sunlight or Ultraviolet (UV) radiation.